...read the wave
Nano Medicine...Nano Medizin...
Nano Geneeskunde...Nano Medicína
www.nanoTsunami.com

 

Nanobac Life Sciences Announces
Research Collaboration with UCSF and NASA's Johnson Space Center to Study Kidney Stones

 

 

TAMPA, Fla.--(BUSINESS WIRE)--June 9, 2005--Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") announced today a multi-center collaboration involving researchers from Nanobac Life Sciences, the University of California, San Francisco (UCSF), and NASA's Johnson Space Center, to study kidney stone formation. The multi-disciplinary team will apply the same type of instrumentation used to analyze moon rocks and particles collected from space to analyze mineralized particles and stones collected from kidney stone patients.

Little progress has been made during the last 50 years in understanding kidney stone formation. However, researchers from Nanobac have shown that virtually all kidney stones contain Calcifying Nano-Particles, also referred to as "Nanobacteria". Nanobac researchers have also shown that these particles are powerful mediators of plaque formation and stones. The direct injection of Nanobacteria into rat kidneys resulted in stone formation in the nanobacteria-injected kidney during one month follow-up. The multi-disciplinary team will attempt to find early events in stone formation and to verify whether Calcifying Nano-Particles are the initiators of kidney stone formation.

"This collaboration is unique as it brings together Nanobac's expertise in Calcifying Nano-Particles, with one of the leading urologists in the field of kidney stone disease, Dr. Marshall Stoller from UCSF. Through Nanobac's Space Act Agreement with NASA, Dr. Neva Ciftcioglu, Nanobac's researcher at NASA, and a team of biomaterial researchers, headed by Dr. David McKay, will apply some of the world's most sophisticated instruments for studying mineralized samples," stated Grant Carlson, Nanobac's President and Chief Operating Officer. "This collaboration could have far reaching implications for the 1 person in 10 that develops kidney stones in their lifetime."

"Although urinary stones comprise the third most common disease of the urinary tract, the underlying cause still remains a mystery," commented Dr. Marshall Stoller, Vice Chairman, Department of Urology, University of California, San Francisco. "This is a rare opportunity to apply some of the most advanced geological analysis technologies, previously used to study lunar samples, to study mineralized particles from diseased tissues."

NASA says previous data show that astronauts are at increased risk for kidney stones as the result of longer missions and the physiological effects of space. "There could be serious health consequences for an astronaut who develops a kidney stone during a space flight, and it could also harm the mission," stated Dr. Jeffrey Jones, urologist and NASA Flight Surgeon. "By applying technologies from the material sciences, we hope to solve a medical mystery. What is the underlying cause of kidney stones and can they be prevented? The answer to those questions will have a significant impact to Americans and to astronaut health on extended space missions."

The economic costs of kidney stones are enormous. In the U.S., more than half a million people will develop kidney stones this year and 7 to 10 of every 1,000 hospital admissions are due to kidney stones. Men appear to be afflicted with kidney stones more often than women, with the ratio being about 3 to 1. In addition, those who develop kidney stones have a 50% risk of having another stone within 5-10 years. Caucasian patients are affected by kidney stones more than African American patients, and the maximum incidence occurs in the 30-50 year old age group.

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Calcifying Nano-Particles, also referred to as "Nanobacteria". The Company's pioneering research is establishing the pathogenic role of Nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac has identified and established two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nanobacterial infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our websites at: http://www.nanobaclifesciences.com or http://www.nanobacsciences.com .

 


This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo

 

or how about joining us

 

or contacting us ?

 


about us

 

our mission